Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Research & Development: 2019-2024

Historic Research & Development for Lyell Immunopharma (LYEL) over the last 6 years, with Dec 2024 value amounting to $171.6 million.

  • Lyell Immunopharma's Research & Development fell 28.68% to $28.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $155.1 million, marking a year-over-year decrease of 8.70%. This contributed to the annual value of $171.6 million for FY2024, which is 6.20% down from last year.
  • Per Lyell Immunopharma's latest filing, its Research & Development stood at $171.6 million for FY2024, which was down 6.20% from $182.9 million recorded in FY2023.
  • Over the past 5 years, Lyell Immunopharma's Research & Development peaked at $182.9 million during FY2023, and registered a low of $138.7 million during FY2021.
  • Moreover, its 3-year median value for Research & Development was $171.6 million (2024), whereas its average is $171.2 million.
  • Its Research & Development has fluctuated over the past 5 years, first soared by 186.57% in 2020, then fell by 23.90% in 2021.
  • Over the past 5 years, Lyell Immunopharma's Research & Development (Yearly) stood at $182.2 million in 2020, then declined by 23.90% to $138.7 million in 2021, then increased by 14.78% to $159.2 million in 2022, then grew by 14.92% to $182.9 million in 2023, then declined by 6.20% to $171.6 million in 2024.